From Standards to Startup: Tim Maye Shapes the Future of Biologics

SAN FRANCISCO, CA – October 06, 2026 – In the fast-paced world of biotechnology and regenerative medicine, the line between regulatory compliance and commercial innovation is often viewed as a battlefield. Entrepreneurs frequently see standard-setting bodies as hurdles to clear, rather than foundations to build upon. Yet, the most enduring companies are often those whose architects understand the rules of the game so intimately that they helped write them. Tonight, at the Association for Advancing Tissue and Biologics (AATB) Congress 26 in San Francisco, that rare intersection of regulatory foresight and entrepreneurial execution takes center stage.

Tim Maye, the Chief Executive Officer of Boca Raton-based C5 Biomedical LLC, is being honored as one of the "50 at 50" by the AATB. This one-time award, marking the association's 50th anniversary, recognizes a select group of fifty individuals who have fundamentally shaped the tissue and biologics field over the past half-century. For observers of strategic growth in the healthcare sector, Maye's trajectory from a dedicated volunteer shaping industry standards to the founder of a thriving, FDA-registered biologics manufacturer offers a masterclass in building a company with a compliance-first operational architecture.

Writing the Rules of the Game

To understand the significance of this recognition, one must look at the mechanics of the tissue banking industry. The AATB is the premier standard-setting body for the safety and use of donated human tissue in the United States. Its accreditation is a rigorous, highly sought-after mark of quality that sits atop mandatory FDA registrations. For six years, Tim Maye chaired the AATB's Standards Committee, guiding the very frameworks that govern how human cells, tissues, and cellular and tissue-based products (HCT/Ps) are recovered, processed, and distributed.

With a career spanning 28 years in tissue banking and biologics, and having held his Certified Tissue Bank Specialist (CTBS) credential since 1999, Maye's influence on the sector's safety protocols is deeply embedded in its current operations.

"Tim chaired the AATB Standards Committee for six years, during which time I had the opportunity to be the liaison to this extremely important and impactful committee," said Beverly Bliss, MBA, CTBS, former AATB Vice President of Accreditation and Standards. "The foundation of the Association has always been the establishment and refinement of our Standards for Tissue Banking, and Tim was able to continue that legacy without missing a beat. Tim brought cohesion and calm leadership to his role, completely voluntary, that allowed members of the committee to discuss and debate the issues to achieve best outcomes."

This background is what makes the foundation of C5 Biomedical, launched by Maye in 2021, so compelling from a business strategy perspective. When C5 Biomedical earned its official AATB accreditation in November 2025, it did so under the exact standards its founder helped draft.

"This recognition belongs to everyone who's helped raise the bar in tissue banking over the last three decades," said Tim Maye, CTBS, CEO of C5 Biomedical. "I've had the privilege of helping write some of the standards this industry runs on today, and I'm not finished. I still sit on that committee, and there's more work ahead I want to see through."

The '50 at 50' Milestone and the Evolution of Biologics

The AATB's 50th anniversary is more than a ceremonial milestone; it is a moment to reflect on how far regenerative medicine has come. Fifty years ago, tissue banking was a nascent field primarily focused on basic skin and bone grafts for severe trauma. Today, it is a sophisticated, multi-billion-dollar global industry driving advancements in everything from spinal fusion to advanced wound care.

The "50 at 50" honorees represent the pioneers who navigated this complex evolution. They are the scientists, regulators, and executives who transformed biological materials into reliable, life-saving surgical tools. Birth tissue and amniotic membranes, in particular, have shifted from being discarded medical waste to highly prized biological scaffolds rich in growth factors and regenerative properties.

This is precisely the arena where C5 Biomedical operates. The company specializes in the manufacture of amniotic membrane allografts. These products serve as biological barriers and regenerative aids across a wide spectrum of surgical applications, including wound care, burn treatment, ocular procedures, spine, and orthopedic surgeries.

Navigating a Highly Competitive Regenerative Market

The market for biologic scaffolds and amniotic tissue is intensely competitive. C5 Biomedical is navigating a landscape populated by established, publicly traded giants known for their extensive regenerative medicine portfolios. For a newer entrant founded in 2021 to carve out market share, it requires more than just a good product; it demands an unimpeachable reputation for quality and safety.

This is where the strategic advantage of a founder's background becomes apparent. C5 Biomedical has developed a robust portfolio of proprietary product lines, including AéroGuard™, NéoGuard™, xPatch™, and iPatch™. Beyond its own branded products, the company also leverages its manufacturing capabilities to produce private-label allografts for third-party medical distributors.

Industry analysts frequently note that in the HCT/P market, regulatory scrutiny is a constant headwind. The FDA continuously monitors these products to ensure they meet strict criteria for homologous use and minimal manipulation. By operating an FDA-registered and AATB-accredited facility, C5 Biomedical effectively utilizes its rigorous compliance as a competitive moat. Distributors and surgeons alike demand absolute certainty regarding the provenance, processing, and safety of the allografts they utilize. A manufacturing operation built by a former AATB Standards Committee chair inherently projects that required level of trust and operational excellence.

The Strategic Advantage of Compliance-First Operations

From an operational standpoint, the story of C5 Biomedical highlights a crucial lesson for modern business leaders in highly regulated sectors. Often, startups attempt to innovate first and figure out compliance later—a strategy that frequently leads to costly regulatory roadblocks, product recalls, or complete operational shutdowns.

Maye's approach flips this paradigm. By embedding a deep, foundational understanding of industry standards into the company's DNA from day one, C5 Biomedical was able to streamline its path to market and secure critical accreditations efficiently. Earning AATB accreditation typically requires a minimum of six months of flawless operation in compliance with the association's stringent standards. Achieving this milestone in November 2025 demonstrated that C5 Biomedical's internal quality systems were operating at peak efficiency.

As the demand for regenerative therapies continues to surge—driven by an aging population, the rising prevalence of chronic wounds such as diabetic foot ulcers, and the continuous push for better surgical outcomes—the role of standardized, high-quality tissue manufacturing will only grow in importance. The next era of biologics will be defined by companies that can scale their operations without compromising the delicate biological integrity of their products.

The recognition of Tim Maye among the "50 at 50" honorees is a testament to the fact that true industry leadership is not just about bringing new products to market. It is about actively participating in the creation of the ecosystems that allow those products to be used safely and effectively. As C5 Biomedical continues to expand its footprint in the amniotic membrane market, it does so on a foundation built over nearly three decades of dedicated service to the broader medical community.